

Table. Self-Reported Status of Immunosuppression for 2021

	Unweighted data, No. (%)		Weighted prevalence per 100 US population, % (95% CI)
	Total sample (N = 29 164)	Had immunosuppression (n = 2123)	
Had immunosuppression		2123 (7.2) ^a	6.6 (6.2-6.9)
Sex			
Male	13 246 (45.4)	737 (35.3)	5.2 (4.8-5.7)
Female	15 918 (54.6)	1351 (64.7)	7.9 (7.4-8.4)
Race and ethnicity ^b			
Hispanic	4044 (13.9)	229 (11.0)	5.0 (4.3-5.8)
Non-Hispanic			
African American or Black	3126 (10.7)	222 (10.6)	6.1 (5.2-7.2)
American Indian or Alaska Native	401 (1.4)	43 (2.1)	8.4 (6.0-11.7)
Asian	1774 (6.1)	70 (3.3)	3.7 (2.8-4.8)
White	19 458 (66.7)	1508 (72.2)	7.4 (6.9-7.8)
Other ^c	361 (1.2)	16 (0.8)	4.2 (2.3-7.3)
Age group, y			
18-29	3836 (13.2)	141 (6.8)	3.3 (2.8-4.0)
30-39	4713 (16.2)	224 (10.7)	4.5 (3.8-5.2)
40-49	4341 (14.9)	300 (14.4)	6.6 (5.8-7.4)
50-59	4731 (16.2)	422 (20.2)	8.7 (7.8-9.6)
60-69	5341 (18.3)	514 (24.6)	9.5 (8.6-10.5)
70-79	4059 (13.9)	355 (17.0)	8.9 (7.9-10.0)
≥80	2143 (7.3)	132 (6.3)	6.6 (5.4-8.1)
Health insurance status			
Insured	27 210 (93.3)	2018 (96.6)	6.9 (6.6-7.3)
Uninsured	1954 (6.7)	70 (3.4)	3.0 (2.2-3.9)

^a Based on responses to the 5 survey questions presented in the Box. Immunosuppression was present if the participant responded “yes” to question 1 or question 2 or if the participant reported having hematologic cancer within the past 2 years (based on question 4 and date calculations from question 5). Those not meeting this definition were categorized as not having immunosuppression.

^b Hispanic or non-Hispanic ethnicity was asked separately from race in the NHIS.

^c The NHIS includes a choice for “some other race” in the questionnaire for respondents who do not identify with the racial and ethnic categories provided.